Zyprexa Zydis
Categorie
Zyprexa Zydis Les marques, Zyprexa Zydis Analogs
Zyprexa Zydis Les marques melange
Zyprexa Zydis Formule chimique
C17H20N4S
Zyprexa Zydis RX lien
http://www.rxlist.com/cgi/generic3/symbyax.htm
Zyprexa Zydis FDA fiche
Zyprexa Zydis msds (fiche de securite des materiaux)
Zyprexa Zydis Synthese de reference
JK Chakrabarti et al., US. 5,229,382 (1991)
Zyprexa Zydis Poids moleculaire
312.434 g/mol
Zyprexa Zydis Point de fusion
195oC
Zyprexa Zydis H2O Solubilite
Aucune information disponible
Zyprexa Zydis Etat
Solid
Zyprexa Zydis LogP
2.199
Zyprexa Zydis Formes pharmaceutiques
Tablet (oral)
Zyprexa Zydis Indication
Pour le traitement de la schizophrénie et la maniaco-dépression (trouble bipolaire).
Zyprexa Zydis Pharmacologie
L'olanzapine, un antipsychotique atypique, est utilisé pour traiter les symptômes positifs et négatifs de la schizophrénie, la manie aiguë avec le trouble bipolaire, l'agitation et des symptômes psychotiques dans la démence. Futur utilisations peuvent inclure le traitement du trouble obsessionnel-compulsif et troubles graves du comportement dans l'autisme. Structurellement et pharmacologique similaire à la clozapine, l'olanzapine se lie à l'alpha (1), la dopamine, , L'histamine H1, muscariniques, et 2 de type sérotonine (5-HT2) récepteurs.
Zyprexa Zydis Absorption
Eh bien absorbé, avec environ 40% de la dose métabolisée avant d'atteindre la circulation systémique.
Zyprexa Zydis Toxicite
Aucune information disponible
Zyprexa Zydis Information pour les patients
PATIENT INFORMATION
Physicians are advised to discuss the following issues with patients for whom they prescribe
olanzapine:
Orthostatic Hypotension: Patients should be advised of the risk of orthostatic hypotension,
especially during the period of initial dose titration and in association with the use of
concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam
or alcohol.
Interference with Cognitive and Motor Performance: Because olanzapine has the potential to
impair judgment, thinking, or motor skills, patients should be cautioned about operating
hazardous machinery, including automobiles, until they are reasonably certain that olanzapine
therapy does not affect them adversely.
Pregnancy: Patients should be advised to notify their physician if they become pregnant or
intend to become pregnant during therapy with olanzapine.
Nursing: Patients should be advised not to breast-feed an infant if they are taking olanzapine.
Concomitant Medication: Patients should be advised to inform their physicians if they are taking,
or plan to take, any prescription or over-the-counter drugs, since there is a potential for
interactions.
Alcohol: Patients should be advised to avoid alcohol while taking olanzapine.
Heat Exposure and Dehydration: Patients should be advised regarding appropriate care in avoiding
overheating and dehydration.
Phenylketonurics: ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) contains phenylalanine
(0.34, 0.45, 0.67, or 0.90 mg per 5, 10, 15, or 20mg tablet, respectively).
Laboratory Tests
Periodic assessment of transaminases is recommended in patients with significant hepatic disease.
Physicians are advised to discuss the following issues with patients for whom they prescribe
olanzapine:
Orthostatic Hypotension: Patients should be advised of the risk of orthostatic hypotension,
especially during the period of initial dose titration and in association with the use of
concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam
or alcohol.
Interference with Cognitive and Motor Performance: Because olanzapine has the potential to
impair judgment, thinking, or motor skills, patients should be cautioned about operating
hazardous machinery, including automobiles, until they are reasonably certain that olanzapine
therapy does not affect them adversely.
Pregnancy: Patients should be advised to notify their physician if they become pregnant or
intend to become pregnant during therapy with olanzapine.
Nursing: Patients should be advised not to breast-feed an infant if they are taking olanzapine.
Concomitant Medication: Patients should be advised to inform their physicians if they are taking,
or plan to take, any prescription or over-the-counter drugs, since there is a potential for
interactions.
Alcohol: Patients should be advised to avoid alcohol while taking olanzapine.
Heat Exposure and Dehydration: Patients should be advised regarding appropriate care in avoiding
overheating and dehydration.
Phenylketonurics: ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) contains phenylalanine
(0.34, 0.45, 0.67, or 0.90 mg per 5, 10, 15, or 20mg tablet, respectively).
Laboratory Tests
Periodic assessment of transaminases is recommended in patients with significant hepatic disease.
Zyprexa Zydis Organismes affectes
Les humains et autres mammifères
